Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etidronate for Arterial Calcifications due to Deficiency in CD73 (ACDC)
NCT01585402Phase 2Completed
- Sponsor
- National Heart, Lung, and Blood Institute
- Start
- Aug 2012
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of etidronate in Arterial Calcification due to Deficiency of CD73 (ACDC), sponsored by National Heart, Lung, and Blood Institute. Primary endpoints: Ankle-brachial Index at Rest at 3 years, Ankle-brachial Index After Exercise at 3 years and 1 more. Started Aug 2012; status: completed.
02
Drugs
etidronate
03
Conditions
Arterial Calcification due to Deficiency of CD73 (ACDC)
Beyond the preview
Go deeper on NCT01585402.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01585402.